GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sigyn Therapeutics SIGY · USD

N/A · US listing · 🇺🇸 United States

Compare

0.03

0.00%

Close of 5 Nov 2026, in USD

About Sigyn Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Sigyn Therapeutics is based in Beverly Hills, California and is incorporated in Delaware. Its shares trade on OTC under the ticker SIGY. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2019, it reported revenue of $143,322.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
28 Jan 2016
Employees
4
Head office
9190 W OLYMPIC BLVD # 263, BEVERLY HILLS, CA, 90212
Incorporated in
DE
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. James JoyceChairman of the Board, Chief Executive Officer, Interim Chief Financial Officer, since 2020$501,878
  • Mr. Craig RobertsChief Technology Officer, Director, since 2020$258,990
  • Mr. Jim DorstIndependent Director
  • Ms. Charlene OwenInvestor Relations, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Sigyn Therapy addresses unmet needs in global health with broad-spectrum blood purification technology.
  • Sigyn Therapy is deployable on global hemodialysis infrastructure for endotoxemia and sepsis treatment.
  • ChemoPrep and ChemoPure enhance chemotherapy delivery and reduce cancer metastasis spread.

Weaknesses

  • The company has only 4 full-time employees, limiting operational capacity.
  • Sigyn Therapeutics has a single product candidate, Sigyn Therapy, for blood purification.
  • The company's IPO on 28 January 2016 indicates limited market presence.

Opportunities

  • Expanding Sigyn Therapy to treat community-acquired pneumonia in infectious disease settings.
  • Leveraging hemodialysis infrastructure for pandemic threat response globally.
  • Integrating ChemoPrep and ChemoPure into cancer treatment systems for enhanced efficacy.

Threats

  • Sepsis remains a leading cause of hospital deaths, increasing competition for treatment solutions.
  • End-stage renal disease patients face high inflammation risks requiring new therapies.
  • Emerging pandemic threats demand rapid development of blood purification technologies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.